Recombinant PTH reduces fractures

Nycomed has launched Preotact, a recombinant human parathyroid hormone licensed for the treatment of osteoporosis in postmenopausal women at high risk of fractures.

The recommended dose of Preotact is 100 micrograms once daily self administered by the patient as a subcutaneous injection into the abdomen.

Trials in women with postmenopausal osteoporosis at this dose level and receiving daily calcium and vitamin D supplements for a period of 18 months produced a significant reduction in the incidence of vertebral fractures, but not in the incidence of non-vertebral fractures. Risk reduction of vertebral fractures was highest in those women with previous fractures and in those with a lumbar spine T-score of less than -3.

Further information: Nycomed UK Ltd, The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA. Tel: 01865 784500.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more